Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2021-11-25 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
CS - PHARMANUTRA SPA - RILASCIATI TRE NUOVI ATTESTATI DI BREVETTO
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by 'CS -' in the header and the structure) announcing that PharmaNutra S.p.A. has been granted three new patents (two in Italy for a new ingredient and formulation upgrade, and one in Russia for Cetylated Fatty Acids). This type of announcement, focusing on intellectual property and strategic assets, is not explicitly covered by the core financial reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, CAP). It relates to the company's core assets and future development. Since the document is a formal announcement about strategic assets (patents) and not a general regulatory filing (RNS) or a report itself, it best fits under a category related to corporate strategy or intellectual property. However, none of the provided codes perfectly match 'Patent Grant Announcement'. Given the options, this announcement details a significant development related to the company's technology and assets, which often accompanies Investor Presentations (IP) or is a standalone regulatory disclosure. Since it is a formal communication about a strategic asset (patent), and it is not a standard financial report, it is most closely related to general corporate information. Given the options, and recognizing that patent grants are often disclosed via regulatory channels, the most appropriate general category for a non-financial, non-management change announcement that is not a standard report is 'Regulatory Filings' (RNS) or potentially 'Investor Presentation' (IP) if it were a slide deck. Since this is a formal press release detailing strategic IP news, and it is not a standard financial report, 'RNS' (Regulatory Filings/General Announcement) is the safest fallback, although 'IP' might be considered if the content were more strategic/forward-looking presentation style. Given the content is a factual announcement of a legal/IP event, RNS is the best fit as a general regulatory disclosure.
2021-11-25 Italian
PR - PHARMANUTRA SPA Distribution agreement Argentina
Regulatory Filings Classification · 1% confidence The document is an official communication identified by the header 'Informazione Regolamentata' (Regulated Information) and a specific filing number (154256) from Euronext Star Milan. The subject ('Oggetto') is 'PR - PHARMANUTRA SPA Distribution agreement Argentina'. The content details the signing of a new international distribution agreement for SiderAL® products in Argentina. This is a specific corporate event announcement, not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a proxy statement. Since it announces a significant business development (a new international agreement), it fits best under the general category for regulatory announcements that are not covered by more specific codes like DIV, CAP, or MANG. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate classification for this type of market-sensitive, non-financial disclosure, although 'LTR' (Legal Proceedings Report) or 'TAR' (M&A Activity) are clearly incorrect. It is a specific business update, which often falls into the general regulatory announcement bucket if a more specific code isn't available. Since it is a specific business agreement announcement, and not a general 'Report Publication Announcement' (RPA) which usually announces the release of another document, RNS is the best fit as a general regulatory disclosure.
2021-11-16 English
CS - PHARMANUTRA SPA Accordo distribuzione Argentina
Regulatory Filings Classification · 1% confidence The document is an official communication from PHARMANUTRA S.P.A. dated November 16, 2021, identified by the header 'Informazione Regolamentata n. 20106-57-2021' and the object 'CS - PHARMANUTRA SPA Accordo distribuzione Argentina'. The content details a new distribution agreement for their SiderAL® line in Argentina. This type of announcement, which communicates a significant business event (like a partnership or contract) to the market via a regulatory channel (Euronext Star Milan), is typically classified as a general Regulatory Filing or sometimes an Earnings Release if it contained financial results. Since it is a specific business development announcement that doesn't fit the definitions for 10-K, IR, ER, or M&A, and it is a formal communication ('CS' likely standing for Comunicato Stampa/Press Release), the most appropriate general category for significant, non-standard regulatory news is RNS (Regulatory Filings). It is not a short announcement pointing to a larger report, so RPA is less likely than RNS for this specific content type.
2021-11-16 Italian
CS - PHARMANUTRA SPA Interim Financial Report as of 30 September 2021
Report Publication Announcement Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from an Italian company (PHARMANUTRA) dated November 12, 2021. The subject line explicitly states: 'CS - PHARMANUTRA SPA Interim Financial Report as of 30 September 2021'. The body of the text confirms that the 'Interim Financial Report as of 30th September 2021' is now available and directs the reader to see the attachment ('Vedi allegato'). Since the document itself is an announcement stating that the comprehensive financial report for an interim period (nine months ended September 30) has been published, and it is very short (under 5,000 characters), it fits the definition of a Report Publication Announcement (RPA) rather than the full Interim Report (IR) itself. The key indicator is the announcement structure pointing to an attached/available report.
2021-11-12 English
CS - PHARMANUTRA SPA - Deposito del Resoconto Intermedio di Gestione al 30 settembre 2021
Report Publication Announcement Classification · 1% confidence The document is a formal announcement (Informazione Regolamentata) from PHARMANUTRA S.P.A. The subject line explicitly states: 'CS - PHARMANUTRA SPA - Deposito del Resoconto Intermedio di Gestione al 30 settembre 2021' (Filing of the Interim Management Report as of September 30, 2021). The text confirms that the 'Resoconto Intermedio di Gestione' (Interim Management Report) is now available to the public. Since the document itself is a short announcement stating that the full report has been filed/published, and it is not the comprehensive report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (4626 chars) is also consistent with a brief announcement rather than a full quarterly report (IR).
2021-11-12 Italian
PHARMANUTRA SPA - INTERIM MANAGEMENT REPORT AS AT 30 SEPTEMBER 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM MANAGEMENT REPORT' and covers the period ending 30 September 2021. It contains comprehensive financial statements, including a consolidated income statement, balance sheet, and explanatory notes. It is not an announcement of a report, but the report itself, and it provides substantive financial data for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2021
2021-11-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.